Meningoencephalitis Diagnosis and Treatment in Canine Patients

Meningoencephalitis in dogs encompasses a spectrum of inflammatory conditions of the central nervous system, ranging from steroid-responsive meningitis-arteritis to necrotizing and granulomatous subtypes grouped under meningoencephalitis of unknown origin (MUO). Clinical suspicion arises from acute onset of neurological signs—fever, neck pain, seizures and variable degrees of paresis—prompting magnetic resonance imaging to characterise lesion distribution, signal changes and contrast enhancement. Cerebrospinal fluid (CSF) analysis remains pivotal, with pleocytosis and elevated protein suggesting immune-mediated or infectious processes. Recent advances have focussed on molecular biomarkers in CSF, integrating neurofilament light chain, tau and neuron specific enolase as quantitative measures of neuronal injury. Treatment typically begins with high-dose glucocorticoids, often combined with second-line immunosuppressants such as cytarabine or cyclosporine to optimise control and minimise steroid side effects. Supportive care and physiotherapy enhance recovery, while standardised clinical scales are under development to monitor disease severity and guide therapeutic adjustments. Despite improved diagnostic precision, long-term outcomes vary, underscoring the need for randomised trials and exploration of novel immunomodulatory strategies.

Research from Nature Portfolio

Recent studies have evaluated CSF biomarkers to refine MUO diagnosis and monitoring. Analysis of neurofilament light chain, tau and neuron specific enolase in canine CSF demonstrated that combined elevations of these markers correlate tightly with disease activity in MUO, distinguishing it from neoplastic and non-inflammatory myelopathies. These findings suggest that multiplex biomarker panels may enable earlier and more accurate diagnosis, inform prognosis and provide objective end points for future therapeutic trials.

Meningoencephalitis Diagnosis and Treatment in Canine Patients publication trend

The graph below shows the total number of articles in meningoencephalitis diagnosis and treatment in canine patients across all publications each year (not limited to Nature Index journals).

Technical terms

Meningoencephalitis of unknown origin (MUO): A group of non-infectious inflammatory brain diseases in dogs without identifiable pathogens.

Cerebrospinal fluid (CSF): The clear fluid surrounding the brain and spinal cord, sampled to assess cell counts, protein and biomarkers.

Neurofilament light chain (NfL): A structural neuronal protein released into CSF during axonal damage.

Neuron specific enolase (NSE): A glycolytic enzyme indicative of neuronal injury when elevated in CSF.

Cytarabine: A cytosine arabinoside antimetabolite used as an adjunct immunosuppressive agent.

Glucocorticoids: Steroid hormones that reduce inflammation and modulate immune responses.

Pleocytosis: An increased number of white blood cells in CSF, reflecting central nervous system inflammation.

Neurodisability scale (NDS): A clinical scoring system to quantify neurological severity and monitor treatment response.

References

1. On the utility of cerebrospinal fluid biomarkers in canine neurological disorders. Scientific Reports (2024).
2. New insights into the treatment of meningoencephalomyelitis of unknown origin since 2009: A review of 671 cases. Frontiers in Veterinary Science (2023).
3. Treatment With Cytarabine at Initiation of Therapy With Cyclosporine and Glucocorticoids for Dogs With Meningoencephalomyelitis of Unknown Origin Is Not Associated With Improved Outcomes. Frontiers in Veterinary Science (2022).
4. Development of a reliable clinical assessment tool for meningoencephalitis in dogs: The neurodisability scale. Journal of Veterinary Internal Medicine (2023).